title: Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
abstract: Topical diphencyprone (DPCP) can be used to treat in transit and cutaneously metastastatic melanoma. To date, 50 patients have received DPCP therapy for at least 1 month at our institution, with complete clearance of cutaneous disease in 46% and partial response in a further 38% of patients. Topical immunotherapy with DPCP is inexpensive and well-tolerated and should be considered in patients with skin metastases unsuitable for or refractory to other forms of therapy.
authors: Department of Dermatology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; The University of Sydney at Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Melanoma Institute Australia, North Sydney, New South Wales, Australia.
authors: Diona L
authors: DL
authors: Damian
authors: Robyn P M
authors: RP
authors: Saw
authors: John F
authors: JF
authors: Thompson
mesh_terms: D000287:Administration, Topical; D000818:Animals; D003521:Cyclopropanes / Q000008:administration & dosage*; D003877:Dermatitis, Contact / Q000209:etiology / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*
chemical_list: D003521:Cyclopropanes; C029402:diphenylcyclopropenone
keywords: contact hypersensitivity; diphenlycyclopropenone